Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brepocitinib - Priovant Therapeutics

Drug Profile

Brepocitinib - Priovant Therapeutics

Alternative Names: Brepocitinib tosylate - Pfizer; PF 6700841; PF-06700841; PF-06700841-15; PF-841

Latest Information Update: 08 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Priovant Therapeutics
  • Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Arylsulfonic acids; Bridged-ring heterocyclic compounds; Cyclopropanes; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dermatomyositis
  • Phase II Crohn's disease; Hidradenitis suppurativa; Uveitis
  • Discontinued Alopecia; Alopecia areata; Atopic dermatitis; Lupus vulgaris; Plaque psoriasis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis; Vitiligo

Most Recent Events

  • 27 Nov 2023 Discontinued - Phase-II for Systemic lupus erythematosus (In the elderly, Treatment-experienced, In adults) in USA, Argentina, Australia, Bulgaria, Belgium, Canada, China, Colombia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Italy, Italy, Japan, South Korea, South Korea, Japan, Mexico, Poland, Portugal, Romania, Serbia, Spain, Taiwan, Ukraine, United Kingdom (PO)
  • 27 Nov 2023 Discontinued - Phase-II for Systemic lupus erythematosus (PO)
  • 19 Oct 2023 Pfizer completes a phase-II trial in Crohn's disease (Treatment-experienced, Combination therapy) in USA, Australia, Austria, Bosnia-Herzegovina, Belgium, Canada, Croatia, Czech Republic, Georgia, Germany, Hungary, Italy, South Korea, Lebanon, Lithuania, Slovakia, South Africa, Saudi Arabia, Poland, Russia, Serbia, Spain, Switzerland, Tunisia, Turkey, Ukraine, United Arab Emirates (PO) (NCT03395184)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top